JP2011529886A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529886A5
JP2011529886A5 JP2011521135A JP2011521135A JP2011529886A5 JP 2011529886 A5 JP2011529886 A5 JP 2011529886A5 JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011521135 A JP2011521135 A JP 2011521135A JP 2011529886 A5 JP2011529886 A5 JP 2011529886A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
composition according
dimethylpyridin
difluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011521135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529886A (ja
JP5396474B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/041793 external-priority patent/WO2010014280A1/en
Publication of JP2011529886A publication Critical patent/JP2011529886A/ja
Publication of JP2011529886A5 publication Critical patent/JP2011529886A5/ja
Application granted granted Critical
Publication of JP5396474B2 publication Critical patent/JP5396474B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011521135A 2008-07-31 2009-04-27 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター Expired - Fee Related JP5396474B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8523008P 2008-07-31 2008-07-31
US61/085,230 2008-07-31
PCT/US2009/041793 WO2010014280A1 (en) 2008-07-31 2009-04-27 Pyrazinone modulator of corticotropin-releasing factor receptor activity

Publications (3)

Publication Number Publication Date
JP2011529886A JP2011529886A (ja) 2011-12-15
JP2011529886A5 true JP2011529886A5 (cg-RX-API-DMAC7.html) 2012-05-24
JP5396474B2 JP5396474B2 (ja) 2014-01-22

Family

ID=40651774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521135A Expired - Fee Related JP5396474B2 (ja) 2008-07-31 2009-04-27 副腎皮質刺激ホルモン放出因子受容体活性のピラジノンモジュレーター

Country Status (10)

Country Link
US (2) US7932256B2 (cg-RX-API-DMAC7.html)
EP (1) EP2303867B1 (cg-RX-API-DMAC7.html)
JP (1) JP5396474B2 (cg-RX-API-DMAC7.html)
KR (1) KR20110040870A (cg-RX-API-DMAC7.html)
CN (1) CN102171205B (cg-RX-API-DMAC7.html)
AR (1) AR072639A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009277057A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011000754A (cg-RX-API-DMAC7.html)
TW (1) TW201008926A (cg-RX-API-DMAC7.html)
WO (1) WO2010014280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
IT201900021216A1 (it) 2019-11-14 2021-05-14 Isagro Spa Processo per la preparazione di derivati piridinici e corrispondenti piridil-formammidine
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
CN112552184B (zh) * 2020-12-18 2022-05-10 诚达药业股份有限公司 一种含环丙基手性胺盐酸盐的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270297A (en) * 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
HRP20031096A2 (en) * 2001-06-12 2005-08-31 Neurogen Corporation 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
AU2003278542A1 (en) 2002-11-21 2004-06-15 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators

Similar Documents

Publication Publication Date Title
JP2015502951A5 (cg-RX-API-DMAC7.html)
MY147442A (en) Imidazoquinolines as lipid kinase inhibitors
JP2020502092A5 (cg-RX-API-DMAC7.html)
JP2017533968A5 (cg-RX-API-DMAC7.html)
JP2016503785A5 (cg-RX-API-DMAC7.html)
EP2312945A4 (en) PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
JP2014513110A5 (cg-RX-API-DMAC7.html)
JP2008513516A5 (cg-RX-API-DMAC7.html)
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
NZ604004A (en) Pyridone and aza-pyridone compounds and methods of use
EP2312946A4 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
JP2017524005A5 (cg-RX-API-DMAC7.html)
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
EP2288260A4 (en) TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD
EP2385951A4 (en) PHOSPHORAMIDATE DERIVATIVES FROM GUANOSINE NUCLEOSIDE COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
EP2173344A4 (en) TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL OR NEUROPSYCHIATRIC ILLNESSES BY OCULAR ADMINISTRATION
JP2004517852A5 (cg-RX-API-DMAC7.html)
JP2005510473A5 (cg-RX-API-DMAC7.html)
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
WO2008000469A3 (en) Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom
JP2009510064A5 (cg-RX-API-DMAC7.html)
WO2008130678A3 (en) Rosuvastatin intermediates and process for the preparation of rosuvastatin
HK1206597A1 (en) Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof
JP2015529681A5 (cg-RX-API-DMAC7.html)
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases